Member Directory

on areas of significant unmet medical need. At Novartis Canada, we are committed to working with all stakeholders within the health care ecosystem to ensure that every Canadian has equitable access to the innovative medicines they need. We are determined to be a valued partner and advocate, with a deep understanding of patient needs along the entire care journey – from drug development, to diagnosis, to access and beyond. Part of the way we are doing this is by leveraging data, technology, and partnerships. We foster a work environment and culture that brings out the best in people to fulfil our purpose of reimagining medicine to improve and extend people’s lives. We operate with the understanding that associates are our greatest asset and encourage them to live the values and behaviors that underpin this culture.

needs of people living with a serious chronic disease into innovative medicines and delivery systems, like our insulin pens. Our treatments today are benefiting millions of people living with diabetes, obesity, and rare blood and endocrine diseases. From our labs to our factory floors, we are discovering and developing innovative biological medicines and making them accessible to patients throughout the world.  

drug-resistant bacterial infections. Our team has deep domain expertise in drug discovery, microbiology, and bacterial lipid metabolism, which we use to create novel antibiotics with potential broad-spectrum utility. DeNovaMed moves beyond 'me-too' antibacterial approaches to make truly novel therapies for resistant infections. DeNovaMed is a spin-off from Dalhousie University with operations in Halifax and Toronto. DeNovaMed has two families of patented and patent-pending compounds, one engineered for topical delivery and one for systemic administration. Our preclinical candidate DNM0547 is being evaluated for use in DFI, a debilitating complication of diabetes that exposes over 1 million people per year to the risk of amputation. This drug is also being explored as a treatment for leprous wounds, methicillin-resistant Staph aureus (MRSA) infection, and other skin infections. The latest generation of DeNovaMed antibiotic innovation (over 700 compounds made) has culminated in DNM0904, suitable for systemic administration and therefore potentially applicable against a wide variety of infectious diseases. We are testing DNM0904 in multi-drug-resistant Gram-positive infections, in biodefense applications, and as an adjuvant for use with other antibiotics to treat Gram-negative infections.

on areas of significant unmet medical need. At Novartis Canada, we are committed to working with all stakeholders within the health care ecosystem to ensure that every Canadian has equitable access to the innovative medicines they need. We are determined to be a valued partner and advocate, with a deep understanding of patient needs along the entire care journey – from drug development, to diagnosis, to access and beyond. Part of the way we are doing this is by leveraging data, technology, and partnerships. We foster a work environment and culture that brings out the best in people to fulfil our purpose of reimagining medicine to improve and extend people’s lives. We operate with the understanding that associates are our greatest asset and encourage them to live the values and behaviors that underpin this culture.

needs of people living with a serious chronic disease into innovative medicines and delivery systems, like our insulin pens. Our treatments today are benefiting millions of people living with diabetes, obesity, and rare blood and endocrine diseases. From our labs to our factory floors, we are discovering and developing innovative biological medicines and making them accessible to patients throughout the world.  

drug-resistant bacterial infections. Our team has deep domain expertise in drug discovery, microbiology, and bacterial lipid metabolism, which we use to create novel antibiotics with potential broad-spectrum utility. DeNovaMed moves beyond 'me-too' antibacterial approaches to make truly novel therapies for resistant infections. DeNovaMed is a spin-off from Dalhousie University with operations in Halifax and Toronto. DeNovaMed has two families of patented and patent-pending compounds, one engineered for topical delivery and one for systemic administration. Our preclinical candidate DNM0547 is being evaluated for use in DFI, a debilitating complication of diabetes that exposes over 1 million people per year to the risk of amputation. This drug is also being explored as a treatment for leprous wounds, methicillin-resistant Staph aureus (MRSA) infection, and other skin infections. The latest generation of DeNovaMed antibiotic innovation (over 700 compounds made) has culminated in DNM0904, suitable for systemic administration and therefore potentially applicable against a wide variety of infectious diseases. We are testing DNM0904 in multi-drug-resistant Gram-positive infections, in biodefense applications, and as an adjuvant for use with other antibiotics to treat Gram-negative infections.